Wurmlingen

Surgalign Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System

Retrieved on: 
Thursday, December 15, 2022
Holo, Physician, Surgeon, Annual report, Failure, Communication, Ix, FDA, Vii, XV, MIS, Deformity, UI, Wurmlingen, Standard of care, Xi, COVID-19, Patient, Spine, Medical device, Risk management, Cortera

Surgalign received FDA 510(k) in August 2022 and Cortera and was introduced in a limited market release shortly thereafter.

Key Points: 
  • Surgalign received FDA 510(k) in August 2022 and Cortera and was introduced in a limited market release shortly thereafter.
  • In a little over three months, the Company has successfully penetrated target markets and today announced the completion of the 100th case utilizing this new flagship pedicle screw system.
  • The system boasts a feature-rich screw design that maintains a comparatively low profile and a newly designed locking mechanism.
  • Surgalign markets products throughout the United States and in approximately 50 countries worldwide through an expanding network of top independent distributors.

Surgalign™ Expands Adoption of its HOLO Portal™ Surgical Guidance System in Virginia

Retrieved on: 
Tuesday, December 13, 2022
Holo, AR, Physician, Surgeon, Anatomy, Failure, Communication, Ix, FDA, Vii, XV, Percussion section, Food and Drug Administration, MD, Form 10-K, Wurmlingen, 100,000, Standard of care, AI, Xi, COVID-19, Patient, Medical device, Risk management

HOLO Portal is the world’s first surgical guidance system to incorporate AI and AR.

Key Points: 
  • HOLO Portal is the world’s first surgical guidance system to incorporate AI and AR.
  • This is the first clinical application of Surgalign’s HOLO™ AI digital health platform.
  • The HOLO Portal system uses AR to overlay the segmented AI reconstruction over the patient’s actual anatomy, providing real-time 3D visualization throughout the surgical procedure.
  • In January 2022, Surgalign received U.S. Food & Drug Administration (FDA) 510(k) clearance for use of the HOLO Portal system within lumbar spine procedures.

Surgalign Announces Closing of $12.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Wednesday, November 16, 2022
Holo, COVID-19, Series, File, Communication, Xi, 3rd Floor, Physician, Patient, Prospectus, Annual report, Ix, Standard of care, Security (finance), XV, Vii, Sale, Failure, Park Avenue, Wurmlingen

The gross proceeds to Surgalign from this offering were $12.0 million, before deducting the placement agent's fees and other offering expenses.

Key Points: 
  • The gross proceeds to Surgalign from this offering were $12.0 million, before deducting the placement agent's fees and other offering expenses.
  • A final prospectus supplement and the accompanying prospectus relating to the offering was filed with the SEC.
  • Surgalign markets products throughout the United States and in approximately 50 countries worldwide through an expanding network of top independent distributors.
  • This press release contains forward-looking statements including, without limitation, statements relating the intended use of proceeds from the registered direct offering.

Surgalign Announces $12.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Monday, November 14, 2022
Holo, Sale, Communication, 3rd Floor, File, Failure, Exercise, Series, Xi, XV, Prospectus, Patient, Security (finance), Standard of care, Physician, Ix, Vii, Annual report, COVID-19, Wurmlingen, Park Avenue

The closing of the offering is expected to occur on or about November 16, 2022, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about November 16, 2022, subject to the satisfaction of customary closing conditions.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • The gross proceeds to Surgalign from this offering are expected to be $12.0 million, before deducting the placement agent's fees and other offering expenses.
  • This press release contains forward-looking statements including, without limitation, statements relating to the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering and the intended use of proceeds from the registered direct offering.

Surgalign™ Announces Corporate Restructuring Program to Focus on Key Growth Areas

Retrieved on: 
Wednesday, November 9, 2022
Holo, GLOBE, Vii, Stock, Wurmlingen, Ix, XV, Communication, Research, Rationalization, Xi, Board, COVID-19, SEC, Failure, NASDAQ, Solution, Board of directors, Public expenditure, Company, Form 10-K, Standard of care, Physician, Patient, Growth, Industry, 100,000, Pharmaceutical industry, Risk management

As a result of the restructuring programs and initiatives planned, the Company expects an estimated cash savings of approximately $30.0 to $35.0 million compared to 2022.

Key Points: 
  • As a result of the restructuring programs and initiatives planned, the Company expects an estimated cash savings of approximately $30.0 to $35.0 million compared to 2022.
  • Our focus is on innovation and better serving our customers with the products and support they need to improve patient outcomes.
  • Surgalign markets products throughout the United States and in approximately 50 countries worldwide through an expanding network of top independent distributors.
  • Surgalign is headquartered in Deerfield, IL, with commercial, innovation and design centers in San Diego, CA, Warsaw and Poznan, Poland, and Wurmlingen, Germany.

Surgalign Schedules Third Quarter 2022 Earnings Release for November 2, 2022

Retrieved on: 
Tuesday, October 25, 2022
Physician, LinkedIn, International, U.S. Securities and Exchange Commission, SEC, Webcast, NASDAQ, Patient, Standard of care, Twitter, Industry, Wurmlingen, GLOBE, Forward-looking statement, Solution

Surgalign will host a conference call and audio webcast at 4:30 p.m.

Key Points: 
  • Surgalign will host a conference call and audio webcast at 4:30 p.m.
  • Surgalign Holdings, Inc. is a global medical technology company committed to the promise of digital health to drive transformation across the surgical landscape.
  • Surgalign markets products throughout the United States and in approximately 50 countries worldwide through an expanding network of top independent distributors.
  • Surgalign is headquartered in Deerfield, IL, with commercial, innovation and design centers in San Diego, CA, Warsaw and Poznan, Poland, and Wurmlingen, Germany.

Surgalign™ Awarded 2022 Best New Technology Award from Orthopedics This Week for its HOLO Portal™ Surgical Guidance System

Retrieved on: 
Tuesday, October 11, 2022
Holo, LinkedIn, Physician, U.S. Securities and Exchange Commission, Engineering, SEC, Technology, Percussion section, Anatomy, AR, NASDAQ, Patient, Standard of care, Research, Twitter, McCormick, NASS, Orthopedic surgery, North American Spine Society, Spine, Solution, Company, Industry, AI, CEO, Wurmlingen, Food and Drug Administration, GLOBE, Forward-looking statement, Invention, Robotics, FDA, Â, Surgeon, Neurosurgery, Medicine, Medical device

The 2022 jury of senior spine and neurosurgeons voted Surgaligns HOLO Portal the Best New Technology of 2022.

Key Points: 
  • The 2022 jury of senior spine and neurosurgeons voted Surgaligns HOLO Portal the Best New Technology of 2022.
  • HOLO Portal is the worlds first surgical guidance system to incorporate AI and AR.
  • The HOLO Portal system uses AR to overlay the segmented AI reconstruction over the patients actual anatomy, providing real-time 3D visualization throughout the surgical procedure.
  • In January 2022, the Company received U.S. Food & Drug Administration (FDA) 510(k) clearance for use of the HOLO Portal system within lumbar spine procedures.

Surgalign Holdings, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Retrieved on: 
Thursday, October 6, 2022
LinkedIn, U.S. Securities and Exchange Commission, SEC, Employment, NASDAQ, Patient, Standard of care, Twitter, The Independent, Financial compensation, Industry, Board, GLOBE, Surgeon, Pharmaceutical industry, Nasdaq, Wurmlingen

The award was granted on October 03, 2022 and it was made under the Surgalign Holdings, Inc. 2021 Inducement Plan.

Key Points: 
  • The award was granted on October 03, 2022 and it was made under the Surgalign Holdings, Inc. 2021 Inducement Plan.
  • The awards were approved by the independent Compensation Committee of the Board of Directors of Surgalign Holdings and were granted to the new employees as an inducement material to their acceptance of employment with Surgalign pursuant to Nasdaq rules.
  • Surgalign markets products throughout the United States and in more than 50 countries worldwide through an expanding network of top independent distributors.
  • Surgalign is headquartered in Deerfield, IL, with commercial, innovation and design centers in San Diego, CA, Warsaw and Poznan, Poland and Wurmlingen, Germany.

Surgalign Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures

Retrieved on: 
Monday, September 26, 2022
IBF, Twitter, Neck, U.S. Securities and Exchange Commission, LinkedIn, ACDF, Industry, Patient, Physician, Standard of care, Wurmlingen, Solution, Spine, The Neck, Surgeon, NASDAQ, GLOBE, Titanium, SEC, 3D printing, Dentistry

The new implants include Fortilink-A with TiPlus technology for anterior lumbar interbody fusion (ALIF) procedures; Fortilink-TC and -TS with TiPlus technology for posterior lumbar interbody fusion (PLIF/TLIF) procedures; and Fortilink-C with TiPlus technology for anterior cervical discectomy and fusion (ACDF) procedures.

Key Points: 
  • The new implants include Fortilink-A with TiPlus technology for anterior lumbar interbody fusion (ALIF) procedures; Fortilink-TC and -TS with TiPlus technology for posterior lumbar interbody fusion (PLIF/TLIF) procedures; and Fortilink-C with TiPlus technology for anterior cervical discectomy and fusion (ACDF) procedures.
  • The system features streamlined instrumentation and a wide variety of implant sizes allowing surgeons to implant their preferred choice for the patient.
  • To learn more about the Fortilink portfolio of products sold by Surgalign, please visit: www.surgalign.com .
  • Surgalign markets products throughout the United States and in approximately 50 countries worldwide through an expanding network of top independent distributors.

Surgalign Announces Third Clinical Site in the Commercialization of its HOLO Portal™ Surgical Guidance System

Retrieved on: 
Thursday, September 15, 2022
Twitter, AR, FDA, MD, U.S. Securities and Exchange Commission, Food and Drug Administration, LinkedIn, Company, Industry, Forward-looking statement, Patient, Intelligence, Physician, CEO, Technology, Standard of care, Wurmlingen, Solution, Surgeon, NASDAQ, GLOBE, SEC, Percussion section, AI, Anatomy, Medical device

HOLO Portal, the worlds first surgical guidance system to incorporate AI and AR, represents the initial clinical application of Surgaligns HOLO AI digital health platform.

Key Points: 
  • HOLO Portal, the worlds first surgical guidance system to incorporate AI and AR, represents the initial clinical application of Surgaligns HOLO AI digital health platform.
  • The HOLO Portal system uses AR to overlay the segmented AI reconstruction over the patients actual anatomy, providing real-time 3D visualization throughout the surgical procedure.
  • In January 2022, the Company received U.S. Food & Drug Administration (FDA) 510(k) clearance for use of the HOLO Portal surgical guidance system within lumbar spine procedures.
  • Congratulations to Dr. Chunduri for completing his first surgical case with the SurgalignTM HOLO Portal system, said Terry Rich, President and CEO of Surgalign.